Table 3.
Distribution of clinical parameters according to groups of ERα/PI3K expression
| Duolink ERα/PI3K | Test (p) | ||||
|---|---|---|---|---|---|
| 0–7 (N = 125) | >7 (N = 50) | ||||
| N | % | N | % | ||
| Age at diagnosis (years) | χ2 (0.720) | ||||
| <50 | 39 | 31.2 | 17 | 34.0 | |
| ≥50 | 86 | 68.8 | 33 | 66.0 | |
| Menopause | χ2 (0.925) | ||||
| ND | 3 | 0 | |||
| No | 43 | 35.2 | 18 | 36.0 | |
| Yes | 79 | 64.8 | 32 | 64.0 | |
| Tumour size (mm) | χ2 (0.733) | ||||
| <20 mm | 49 | 39.2 | 21 | 42.0 | |
| ≥20 mm | 76 | 60.8 | 29 | 58.0 | |
| Histological grade (SBR) | χ2 (0.014) | ||||
| 1 | 29 | 23.2 | 3 | 6.0 | |
| 2 | 45 | 36.0 | 27 | 54.0 | |
| 3 | 51 | 40.8 | 20 | 40.0 | |
| Lymph node involvement | Fisher exact (0.205) | ||||
| N0 | 56 | 44.8 | 20 | 40.0 | |
| Micro metastasis | 14 | 11.2 | 2 | 4.0 | |
| Macro metastasis | 55 | 44.0 | 28 | 56.0 | |
| Lympho-vascular invasion | χ2 (0.195) | ||||
| Yes | 61 | 48.8 | 19 | 38.0 | |
| No | 64 | 51.2 | 31 | 62.0 | |
| Oestrogen receptor: % marked cells | χ2 (0.758) | ||||
| ND | 1 | 0 | |||
| <10% | 30 | 24.2 | 11 | 22.0 | |
| ≥10% | 94 | 75.8 | 39 | 78.0 | |
| Progesterone receptor: % marked cells | χ2 (0.386) | ||||
| ND | 1 | 0 | |||
| <10% | 41 | 33.1 | 20 | 40.0 | |
| ≥10% | 83 | 66.9 | 30 | 60.0 | |
| HER2 status | χ2 (0.019) | ||||
| ND | 9 | 1 | |||
| 0/+/++FISH− | 104 | 89.7 | 37 | 75.5 | |
| ++FISH+/+++ | 12 | 10.3 | 12 | 24.5 | |
Clinical parameters (age at diagnosis, tumour size, menopausal status, lymph node involvement, SBR grading and hormonal expression) were analysed for the 175 patients included in the TMA study. Association between clinical characteristics and the level of ERα/PI3K interaction (cut off at 7 dots/cell) was determined using χ2 test or Fisher's exact test. Significant correlations are highlighted in bold characters.